Assembly Biosciences, a biotechnology company based in South San Francisco, develops treatments for chronic hepatitis B and other infectious diseases, with a pipeline including multiple antiviral agents. The company, which went public in December 2010, employs 65 people.
ASMB has been in the news recently: Assembly Biosciences is not mentioned in the provided information, so a summary relevant to it cannot be created. The content primarily discusses political and regulatory issues related to New York governance and public safety.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
